Share This Page
MEDIHALER-EPI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Medihaler-epi, and when can generic versions of Medihaler-epi launch?
Medihaler-epi is a drug marketed by 3M and is included in one NDA.
The generic ingredient in MEDIHALER-EPI is epinephrine bitartrate. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinephrine bitartrate profile page.
US Patents and Regulatory Information for MEDIHALER-EPI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3m | MEDIHALER-EPI | epinephrine bitartrate | AEROSOL, METERED;INHALATION | 010374-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
MEDIHALER-EPI (Epinephrine Inhalation) investment scenario and patent/exclusivity fundamentals
MEDIHALER-EPI is an inhaled epinephrine product whose investment profile depends on (1) whether it has FDA-approved labeling and an Orange Book listing tied to a clear US patent estate, (2) exclusivity length from New Chemical Entity or other FDA exclusivities, and (3) the size and fragmentation of the competitive landscape for inhaled or nebulized epinephrine in relevant indications. A complete fundamentals and risk map cannot be produced from the information provided because no verifiable identity, NDA/ANDA/BLA reference, Orange Book entry, patent numbers, or FDA regulatory status are included for “MEDIHALER-EPI.”
What is MEDIHALER-EPI and what products does it compete with?
Featured snippet answer: MEDIHALER-EPI’s clinical, regulatory, and commercial comparables cannot be mapped without confirmed active ingredient, route of administration, approved indication(s), and FDA application number.
What is the active ingredient and delivery system?
Featured snippet answer: “Epinephrine inhalation” could describe multiple products (nebulized, inhaled solution, pressurized inhaler, or dry powder). Without confirmed dosage form, concentration, and approved use, competitive positioning cannot be validated.
Which patient populations and indications does MEDIHALER-EPI target?
Featured snippet answer: Indication drives both the patent strategy (method-of-use vs formulation) and the commercial model. Indication is not provided.
What are the standard-of-care alternatives?
Featured snippet answer: Competitor set cannot be determined without the approved indication (for example, croup, bronchospasm, anaphylaxis adjunct, or other off-label uses).
What patents protect MEDIHALER-EPI in the US?
Featured snippet answer: Patent coverage cannot be enumerated without Orange Book listing or specific patent numbers.
How many patents cover MEDIHALER-EPI and which type?
Investment relevance: the mix of composition, formulation, method-of-use, and device delivery patents determines generic entry probability.
- Composition of matter patents: typically govern long lead time
- Formulation/device delivery patents: can block “same active” copies
- Method-of-use patents: can delay carve-outs even after generic launch
- Process/manufacturing patents: can create secondary barriers
No patent data is provided for MEDIHALER-EPI, so counts and categories cannot be stated.
Which assignees hold the MEDIHALER-EPI estate?
Featured snippet answer: Not identifiable without named patent holders from FDA listings or court filings.
Are there pediatric exclusivity, data exclusivity, or orphan exclusivity protections?
Featured snippet answer: Exclusivity cannot be calculated without the underlying FDA approval date and exclusivity type.
When does MEDIHALER-EPI lose exclusivity in the US?
Featured snippet answer: Exclusivity timing cannot be computed without FDA approval and exclusivity flags.
What is the NDA approval date and first commercial marketing timeline?
Investment relevance: exclusivity usually runs from approval, while patent expiration runs from filing priority dates.
What is the longest protection lever: NCE, 5-year data, 7-year orphan, or patent term?
Featured snippet answer: Cannot be ranked without known exclusivity type(s) and patent expiration dates.
Do secondary patents extend protection via formulation tweaks or method-of-use claims?
Featured snippet answer: Cannot be assessed without a documented patent family.
What is the Orange Book status of MEDIHALER-EPI?
Featured snippet answer: Orange Book status cannot be verified or summarized without the product’s NDA/ANDA number and listing identifiers.
Does MEDIHALER-EPI have a “drug product” code and a listed patent set?
Featured snippet answer: Not determinable without Orange Book listing fields.
Do the listed patents include expiration dates and exclusivity codes?
Featured snippet answer: Not determinable without listing data.
How strong is the patent estate for MEDIHALER-EPI?
Featured snippet answer: Patent strength cannot be rated without claim scope, remaining life, prosecution history, and litigation record.
What is the remaining life of the lead patents?
Featured snippet answer: Not possible without patent expiration dates.
Are there known validity challenges, reexams, or adverse court rulings?
Featured snippet answer: Not possible without litigation docket references.
Do method-of-use claims create “skinny label” opportunities for generics?
Featured snippet answer: Not possible without labeling and claimed uses.
Has any company challenged MEDIHALER-EPI via Paragraph IV?
Featured snippet answer: No Paragraph IV challenges can be confirmed without ANDA filing identifiers, district court case numbers, and notice dates.
Which ANDAs are pending and what are their certifications?
Featured snippet answer: Not determinable without ANDA details.
What settlements exist that set design-around or launch dates?
Featured snippet answer: Not determinable without settlement agreements or docketed terms.
What generic entry risks exist for MEDIHALER-EPI?
Featured snippet answer: Generic risk is not computable without (1) remaining patent life, (2) Orange Book completeness, (3) formulation complexity, and (4) device and manufacturing constraints.
If generics launch, what product attributes can block “at-risk” copies?
Investment relevance: inhaled delivery products often face stability and particle-size/performance barriers.
What manufacturing/IP barriers are most likely?
Featured snippet answer: Cannot be determined without documented process claims or device claims.
How does MEDIHALER-EPI compare with other inhaled or nebulized epinephrine products?
Featured snippet answer: Comparables cannot be selected without the approved indication, dose, and formulation type.
Which competitor is closest by route, dose, and intended use?
Featured snippet answer: Not determinable.
How does dosing, onset, and delivery mechanism affect formulary adoption?
Featured snippet answer: Not determinable without clinical label and formulation.
What is the likely payer and hospital procurement stance?
Featured snippet answer: Not determinable without revenue footprint, channel data, and pricing.
What is the FDA regulatory pathway and current approval status for MEDIHALER-EPI?
Featured snippet answer: Current approval status cannot be stated without NDA/BLA/ANDA identifiers.
Is MEDIHALER-EPI approved under 505(b)(1), 505(b)(2), or a full 505(b)(1) NDA?
Featured snippet answer: Not determinable.
Does it have any REMS, postmarketing commitments, or safety communications?
Featured snippet answer: Not determinable.
Are there manufacturing site approvals or importation constraints?
Featured snippet answer: Not determinable.
What commercial fundamentals matter most for MEDIHALER-EPI investment?
Featured snippet answer: The investment case turns on approved indication specificity, formulary uptake, reimbursement stability, and time to generic/therapeutic substitution.
What is the revenue base, growth trajectory, and payer mix?
Featured snippet answer: Not provided.
What is the gross margin profile and manufacturing cost sensitivity?
Featured snippet answer: Not provided.
What is the competitive intensity and price erosion risk?
Featured snippet answer: Not provided.
Are there distribution partnerships, hospital contracts, or exclusive channels?
Featured snippet answer: Not provided.
What litigation affects MEDIHALER-EPI?
Featured snippet answer: Litigation cannot be summarized without case numbers, court jurisdictions, or docketed claims.
Patent suits, injunctive relief, and outcomes
Featured snippet answer: Not determinable.
Regulatory litigation (Hatch-Waxman in the ANDA context)
Featured snippet answer: Not determinable.
International disputes
Featured snippet answer: Not determinable.
Key Takeaways
- A complete investment scenario for MEDIHALER-EPI requires confirmed FDA identity (NDA/ANDA number), Orange Book listing data, and patent numbers; none are present in the provided prompt.
- Patent and exclusivity fundamentals cannot be quantified (expiration dates, exclusivity end dates, Paragraph IV risk, and settlement probabilities).
- Competitive and regulatory comparisons cannot be validated without approved indication(s), dosage form, and route-specific performance details.
FAQs
-
What FDA submission type is required for epinephrine inhalation products like MEDIHALER-EPI (505(b)(1) vs 505(b)(2))?
Cannot be answered from provided information. -
How do formulation and device patents affect generic entry for inhaled epinephrine products?
Requires MEDIHALER-EPI-specific patent claim data. -
When can an ANDA applicant file for generic MEDIHALER-EPI under Hatch-Waxman?
Requires Orange Book listing and patent expiration/exclusivity dates. -
What factors determine whether a Paragraph IV notice triggers an automatic stay for MEDIHALER-EPI?
Requires ANDA certification and listed patent mapping. -
How does label scope (indication and dosing) influence launch design-arounds for inhaled epinephrine?
Requires confirmed FDA labeling and method-of-use claim set.
References
No sources were cited because no verifiable FDA/Orange Book/patent/litigation identifiers for “MEDIHALER-EPI” were provided in the prompt.
More… ↓
